Camp4 director granted 56,000 stock options
Camp4 Therapeutics director Michael F. MacLean received a new stock option award for 56,000 shares of common stock.
Rhea-AI Filing Summary
Camp4 Therapeutics director Michael F. MacLean received a new stock option award for 56,000 shares of common stock. The option has an exercise price of $4.46 per share and expires on March 31, 2036. This is a compensation-related grant, not an open-market purchase.
The option covers 56,000 underlying shares and was awarded at no cost on the grant date. The shares underlying the option vest in equal monthly installments over three years starting from the grant date, so MacLean earns the right to exercise portions of the award gradually over time.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 56,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The shares underlying the option vest in equal monthly installments over a period of three years commencing from the date of grant.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
exercise price financial
expiration date financial
vest in equal monthly installments financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Camp4 Therapeutics (CAMP) report for Michael F. MacLean?
What is the exercise price and expiration date of Michael MacLean’s Camp4 stock options?
How do Michael MacLean’s Camp4 (CAMP) stock options vest over time?
Is Michael MacLean’s Camp4 (CAMP) Form 4 transaction an open-market stock purchase?
AI-generated analysis. How Rhea-AI works. Not financial advice.